Edition:
United States

Seattle Genetics Inc (SGEN.O)

SGEN.O on Nasdaq

75.07USD
19 Jul 2019
Change (% chg)

$-1.57 (-2.05%)
Prev Close
$76.64
Open
$76.13
Day's High
$77.06
Day's Low
$74.69
Volume
1,560,757
Avg. Vol
910,442
52-wk High
$84.37
52-wk Low
$50.71

About

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab... (more)

Overall

Beta: 2.04
Market Cap(Mil.): $12,394.23
Shares Outstanding(Mil.): 161.72
Dividend: --
Yield (%): --

Financials

  SGEN.O Industry Sector
P/E (TTM): -- 95.83 34.03
EPS (TTM): -1.74 -- --
ROI: -20.26 7.72 12.70
ROE: -21.08 8.23 17.29

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

Jun 03 2019

UPDATE 1-Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

June 3 An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

Jun 03 2019

CORRECTED-Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

June 3 An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

Jun 03 2019

Earnings vs. Estimates